NASDAQ:ATOS Atossa Therapeutics (ATOS) Stock Price, News & Analysis → Central Bank Gold Heist In Progress (From Colonial Metals) (Ad) Free ATOS Stock Alerts $1.29 0.00 (0.00%) (As of 03/18/2024 ET) Add Compare Share Share Today's Range$1.24▼$1.3450-Day Range$0.80▼$1.3152-Week Range$0.59▼$1.39Volume817,518 shsAverage Volume888,895 shsMarket Capitalization$161.64 millionP/E RatioN/ADividend YieldN/APrice Target$4.50 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get Atossa Therapeutics alerts: Email Address Atossa Therapeutics MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside248.8% Upside$4.50 Price TargetShort InterestBearish5.71% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.41Based on 8 Articles This WeekInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($0.22) to ($0.28) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.0.65 out of 5 starsMedical Sector899th out of 946 stocksPharmaceutical Preparations Industry419th out of 435 stocks 3.5 Analyst's Opinion Consensus RatingAtossa Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $4.50, Atossa Therapeutics has a forecasted upside of 248.8% from its current price of $1.29.Amount of Analyst CoverageAtossa Therapeutics has only been the subject of 2 research reports in the past 90 days. Previous Next 0.0 Short Interest Percentage of Shares Shorted5.71% of the outstanding shares of Atossa Therapeutics have been sold short.Short Interest Ratio / Days to CoverAtossa Therapeutics has a short interest ratio ("days to cover") of 13.6, which indicates bearish sentiment.Change versus previous monthShort interest in Atossa Therapeutics has recently increased by 1.56%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldAtossa Therapeutics does not currently pay a dividend.Dividend GrowthAtossa Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for ATOS. Previous Next 2.5 News and Social Media Coverage News SentimentAtossa Therapeutics has a news sentiment score of 0.41. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.62 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 8 news articles for Atossa Therapeutics this week, compared to 1 article on an average week.Search Interest15 people have searched for ATOS on MarketBeat in the last 30 days. This is an increase of 67% compared to the previous 30 days.MarketBeat FollowsOnly 3 people have added Atossa Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -25% compared to the previous 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Atossa Therapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 7.80% of the stock of Atossa Therapeutics is held by insiders.Percentage Held by InstitutionsOnly 12.74% of the stock of Atossa Therapeutics is held by institutions. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Atossa Therapeutics are expected to decrease in the coming year, from ($0.22) to ($0.28) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Atossa Therapeutics is -5.38, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Atossa Therapeutics is -5.38, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAtossa Therapeutics has a P/B Ratio of 1.39. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Crypto Swap ProfitsClaim Your Complimentary Bitcoin RewardMany have already secured their free Bitcoin reward offered by our esteemed guest. How about you? In an effort to spread the word about our upcoming workshop, he's generously offering $10 in Bitcoin (BTC) to participants. Absolutely no strings attached.Secure Your Spot Now About Atossa Therapeutics Stock (NASDAQ:ATOS)Atossa Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing medicines in the areas of unmet medical need in oncology. The company's lead program is Endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer. It is also developing AT-H201 for lung injury caused by cancer treatment. In addition, the company develops immunotherapy/chimeric antigen receptor therapy programs. It has a research agreement with Dana-Farber Cancer Institute, Inc. to support research of cytokine-coated nanoparticles for the treatment of breast cancer. The company was formerly known as Atossa Genetics Inc. and changed its name to Atossa Therapeutics, Inc. in January 2020. Atossa Therapeutics, Inc. was founded in 2008 and is headquartered in Seattle, Washington.Read More ATOS Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ATOS Stock News HeadlinesMarch 19, 2024 | americanbankingnews.comAtossa Therapeutics (NASDAQ:ATOS) Downgraded by StockNews.com to SellMarch 18, 2024 | globenewswire.comAtossa Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Listing RequirementsMarch 19, 2024 | Crypto Swap Profits (Ad)Claim Your Complimentary Bitcoin RewardMany have already secured their free Bitcoin reward offered by our esteemed guest. How about you? In an effort to spread the word about our upcoming workshop, he's generously offering $10 in Bitcoin (BTC) to participants. Absolutely no strings attached.March 16, 2024 | finance.yahoo.comATOS Apr 2024 4.000 callMarch 12, 2024 | proactiveinvestors.comAtossa Therapeutics adds breast cancer expert to boardMarch 12, 2024 | globenewswire.comAtossa Therapeutics Appoints Breast Cancer Specialist Tessa Cigler, M.D., M.P.H. to its Board of DirectorsMarch 11, 2024 | finance.yahoo.comATOS Oct 2024 2.000 callMarch 9, 2024 | americanbankingnews.comAtossa Therapeutics (NASDAQ:ATOS) Share Price Crosses Above Two Hundred Day Moving Average of $0.81March 19, 2024 | Paradigm Press (Ad)8,788% Return Predicted For THIS Crypto (already up 40% in 6 months)THIS cryptocurrency has gained 40% in 6 months. A crypto millionaire who has researched the space for a decade says it will go up 8,788% in 5 years. The name of this cryptocurrency is revealed right here: March 6, 2024 | proactiveinvestors.comAtossa Therapeutics to present data from ongoing Phase 2 breast cancer trialFebruary 28, 2024 | edition.cnn.comAtossa Therapeutics, Inc.February 24, 2024 | benzinga.comAtossa Therapeutics Stock (NASDAQ:ATOS), Short Interest ReportFebruary 22, 2024 | finanznachrichten.deAtossa Therapeutics, Inc.: Atossa Therapeutics Announces First Patient Dosing of (Z)-Endoxifen in the Ongoing RECAST DCIS StudyFebruary 22, 2024 | proactiveinvestors.comAtossa Therapeutics doses first patient with (Z)-endoxifen in Phase 2 breast cancer trialFebruary 22, 2024 | globenewswire.comAtossa Therapeutics Announces First Patient Dosing of (Z)-Endoxifen in the Ongoing RECAST DCIS StudyFebruary 20, 2024 | au.finance.yahoo.comAtossa Therapeutics, Inc. (YAG2.SG)February 17, 2024 | finance.yahoo.comATOS Mar 2024 1.000 putFebruary 12, 2024 | msn.comAtossa spikes as H.C. Wainwright starts at Buy on lead assetFebruary 7, 2024 | finance.yahoo.comAtossa Therapeutics Announces Full Enrollment of (Z)-Endoxifen Arm of I-SPY 2 Clinical TrialJanuary 27, 2024 | msn.comAtossa Therapeutics progresses Phase II preventative breast cancer therapyDecember 8, 2023 | finance.yahoo.comIs Atossa Genetics (ATOS) Outperforming Other Medical Stocks This Year?December 4, 2023 | proactiveinvestors.comAtossa Therapeutics taps Arezoo Mirad for Senior Medical DirectorDecember 4, 2023 | finance.yahoo.comAtossa Therapeutics Announces the Appointment of Arezoo Mirad, M.D., as Senior Medical DirectorNovember 20, 2023 | finance.yahoo.comAtossa Therapeutics Announces Full Enrollment of Phase 2 Karisma-Endoxifen Clinical TrialNovember 13, 2023 | msn.comAtossa Therapeutics GAAP EPS of -$0.05 beats by $0.02November 13, 2023 | proactiveinvestors.comAtossa Therapeutics advances (Z)-endoxifen for breast cancer research program during 3QNovember 13, 2023 | finance.yahoo.comAtossa Therapeutics Announces Third Quarter 2023 Financial Results and Provides Corporate UpdateSee More Headlines Receive ATOS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Atossa Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings8/14/2023Today3/19/2024Next Earnings (Estimated)3/27/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:ATOS CUSIPN/A CIK1488039 Webatossatherapeutics.com Phone(206) 588-0256Fax206-430-1288Employees11Year Founded2009Price Target and Rating Average Stock Price Target$4.50 High Stock Price Target$5.00 Low Stock Price Target$4.00 Potential Upside/Downside+248.8%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($0.24) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-26,960,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-24.80% Return on Assets-23.82% Debt Debt-to-Equity RatioN/A Current Ratio28.35 Quick Ratio28.35 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.93 per share Price / Book1.39Miscellaneous Outstanding Shares125,300,000Free Float115,530,000Market Cap$161.64 million OptionableOptionable Beta1.16 Social Links 10 Best Cheap Stocks to Buy NowMarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.Get This Free Report Key ExecutivesDr. Steven C. Quay FCAP (Age 73)M.D., Ph.D., Chairman, CEO & President Comp: $1.14MMs. Heather Rees (Age 52)SVP, Finance & Principal Accounting Officer Ms. Delly Behen P.H.R.Vice President of Administration & Human ResourcesMr. Eric Van ZantenVice President of Investor & Public RelationsDr. Richard Graydon M.D.Ph.D., Interim Chief Medical OfficerKey CompetitorsNektar TherapeuticsNASDAQ:NKTRAdicet BioNASDAQ:ACETProQR TherapeuticsNASDAQ:PRQRRelmada TherapeuticsNASDAQ:RLMDKaryopharm TherapeuticsNASDAQ:KPTIView All CompetitorsInstitutional OwnershipGSA Capital Partners LLPBought 101,690 shares on 2/16/2024Ownership: 0.358%Citadel Advisors LLCBought 9,100 shares on 2/15/2024Ownership: 0.000%Northern Trust CorpBought 13,280 shares on 2/13/2024Ownership: 0.182%View All Institutional Transactions ATOS Stock Analysis - Frequently Asked Questions Should I buy or sell Atossa Therapeutics stock right now? 2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Atossa Therapeutics in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" ATOS shares. View ATOS analyst ratings or view top-rated stocks. What is Atossa Therapeutics' stock price target for 2024? 2 brokerages have issued twelve-month price objectives for Atossa Therapeutics' stock. Their ATOS share price targets range from $4.00 to $5.00. On average, they predict the company's stock price to reach $4.50 in the next twelve months. This suggests a possible upside of 248.8% from the stock's current price. View analysts price targets for ATOS or view top-rated stocks among Wall Street analysts. How have ATOS shares performed in 2024? Atossa Therapeutics' stock was trading at $0.88 at the start of the year. Since then, ATOS stock has increased by 46.6% and is now trading at $1.29. View the best growth stocks for 2024 here. When is Atossa Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, March 27th 2024. View our ATOS earnings forecast. How were Atossa Therapeutics' earnings last quarter? Atossa Therapeutics, Inc. (NASDAQ:ATOS) posted its quarterly earnings data on Monday, August, 14th. The company reported ($0.06) earnings per share for the quarter, meeting the consensus estimate of ($0.06). When did Atossa Therapeutics' stock split? Atossa Therapeutics's stock reverse split on Friday, April 20th 2018. The 1-12 reverse split was announced on Friday, April 20th 2018. The number of shares owned by shareholders was adjusted after the market closes on Thursday, April 19th 2018. An investor that had 100 shares of stock prior to the reverse split would have 8 shares after the split. What is Steven C. Quay's approval rating as Atossa Therapeutics' CEO? 8 employees have rated Atossa Therapeutics Chief Executive Officer Steven C. Quay on Glassdoor.com. Steven C. Quay has an approval rating of 53% among the company's employees. This puts Steven C. Quay in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies. 29.0% of employees surveyed would recommend working at Atossa Therapeutics to a friend. What other stocks do shareholders of Atossa Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Atossa Therapeutics investors own include AVEO Pharmaceuticals (AVEO), Alibaba Group (BABA), Heat Biologics (HTBX), Vaxart (VXRT), Biocept (BIOC), MannKind (MNKD), Biopharmx (BPMX), Daré Bioscience (DARE), OPKO Health (OPK) and Nokia Oyj (NOK). Who are Atossa Therapeutics' major shareholders? Atossa Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional investors include GSA Capital Partners LLP (0.36%), Northern Trust Corp (0.18%), Citadel Advisors LLC (0.00%) and Concourse Financial Group Securities Inc. (0.00%). View institutional ownership trends. How do I buy shares of Atossa Therapeutics? Shares of ATOS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:ATOS) was last updated on 3/19/2024 by MarketBeat.com Staff From Our PartnersCentral Bank Gold Heist In ProgressColonial Metals8,788% Return Predicted For THIS Crypto (already up 40% in 6 months)Paradigm PressLike Tiny Crypto Retirement FundsCrypto 101 MediaMake This $3 Trade the Instant the Opening Bell RingsMonument Traders AllianceThe world’s greatest investmentPorter & CompanySHOCKING Footage From Tesla Gigafactory In Austin, TexasInvestorPlaceBitcoin dollar warningStansberry ResearchThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading Academy Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Atossa Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.